Abstract:Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of aberrant cells. Thus, RCD pathways represented by apoptosis have increased in importance as a target for the development of cancer medications in recent years. However, because tumor cells show avoidance to apoptosis, which causes treatment resistance and recurrence, numerous studies have been devoted to alternative cancer cell mortality processes, namely necroptosis, pyroptosis, ferroptosis, and cuproptosis; these RCD modalities have been extensively studied and shown to be crucial to cancer therapy effectiveness. Furthermore, evidence suggests that tumor cells undergoing regulated death may alter the immunogenicity of the tumor microenvironment (TME) to some extent, rendering it more suitable for inhibiting cancer progression and metastasis. In addition, other types of cells and components in the TME undergo the abovementioned forms of death and induce immune attacks on tumor cells, resulting in enhanced antitumor responses. Hence, this review discusses the molecular processes and features of necroptosis, pyroptosis, ferroptosis, and cuproptosis and the effects of these novel RCD modalities on tumor cell proliferation and cancer metastasis. Importantly, it introduces the complex effects of novel forms of tumor cell death on the TME and the regulated death of other cells in the TME that affect tumor biology. It also summarizes the potential agents and nanoparticles that induce or inhibit novel RCD pathways and their therapeutic effects on cancer based on evidence from in vivo and in vitro studies and reports clinical trials in which RCD inducers have been evaluated as treatments for cancer patients. Lastly, we also summarized the impact of modulating the RCD processes on cancer drug resistance and the advantages of adding RCD modulators to cancer treatment over conventional treatments.

Ferroptosis, necroptosis, and pyroptosis in cancer: Crucial cell death types in radiotherapy and post-radiotherapy immune activation

Ferroptosis, Necroptosis, and Pyroptosis in Anticancer Immunity

The scheme, and regulative mechanism of pyroptosis, ferroptosis, and necroptosis in radiation injury

Ferroptosis, radiotherapy, and combination therapeutic strategies

Ferroptosis in cancer and cancer immunotherapy

The Emerging Roles of Nitric Oxide in Ferroptosis and Pyroptosis of Tumor Cells.

Cuproptosis, ferroptosis and PANoptosis in tumor immune microenvironment remodeling and immunotherapy: culprits or new hope

Radiotherapy modulates tumor cell fate decisions: a review

Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities

Pyroptotic cell death: an emerging therapeutic opportunity for radiotherapy

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy

Ferroptosis in cancer immunity and immunotherapy: Multifaceted interplay and clinical implications

Ferroptosis, Necroptosis, and Pyroptosis in Gastrointestinal Cancers: The Chief Culprits of Tumor Progression and Drug Resistance

Ferroptosis, autophagy, tumor and immunity

Ferroptosis-mediated immune responses in cancer

Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy

Ferroptosis, a subtle talk between immune system and cancer cells: To be or not to be?

Ferroptosis and its emerging role in tumor

Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD‐1/PD‐L1 cancer immunotherapy

Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

The crosstalk between oncogenic signaling and ferroptosis in cancer